Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has announced a pivotal advancement in the treatment of acute pain. The U.S. Food and Drug Administration (FDA) has officially accepted the New Drug Application (NDA) for suzetrigine, marking a significant step toward introducing a new class of pain medication. This development could transform the management of moderate-to-severe acute pain, […]
In a major development in the biotechnology industry, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN) have announced a definitive agreement where Vertex will acquire Alpine for $65 per share, amounting to approximately $4.9 billion in cash. This transaction, unanimously approved by both companies’ Boards of Directors, is set to close […]
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics have announced a significant milestone in medical science with the U.S. Food and Drug Administration’s (FDA) approval of CASGEVY (exagamglogene autotemcel [exa-cel]), a revolutionary CRISPR/Cas9 genome-edited cell therapy. This approval marks a significant advancement in the treatment of sickle cell disease (SCD) for patients aged 12 and older experiencing […]
Vertex Pharmaceuticals is set to launch its cystic fibrosis drug KALYDECO (ivacaftor) in New Zealand, which will be available to eligible patients from next month. The US biopharma company said that clinicians can apply for patient access using the exceptional circumstances framework under the Pharmaceutical Management Agency (PHARMAC). Ludovic Fenaux – Senior Vice President of […]